EVEROLIMUS MSDS PDF

Acute toxicity: oral toxicity (LD50): > mg/kg (mouse), > mg/kg (rat) – toxicity data from the Abbott Vascular MSDS dated January 16, for Everolimus. SAFETY DATA SHEET. (in accordance with Regulation (EU) /). Everolimus. Version: 1. Revision date: 29/06/ Page 1 of. Material Safety Data Sheet. Section 1 – Product and Company Information. Product Name: Everolimus. Cat. Code: tlrl-eve. Company identification: InvivoGen.

Author: Akijind Kibar
Country: Liberia
Language: English (Spanish)
Genre: Literature
Published (Last): 21 April 2007
Pages: 362
PDF File Size: 9.33 Mb
ePub File Size: 12.88 Mb
ISBN: 244-7-17674-762-6
Downloads: 26004
Price: Free* [*Free Regsitration Required]
Uploader: Fenrira

Chloroform The serum concentration of Everolimus can be increased when it is combined with Chloroform. Eravacycline The metabolism of Everolimus can be decreased when combined with Eravacycline. Eslicarbazepine acetate The metabolism of Everolimus can be increased when combined with Eslicarbazepine acetate.

Bicalutamide The serum concentration of Everolimus can be increased when it is combined with Bicalutamide. Betrixaban The serum concentration of Betrixaban can be increased when it is mssds with Everolimus. Macitentan The metabolism of Everolimus can be decreased when combined with Macitentan. Potential Health Effects The toxicological properties of this material have not beeninvestigated.

MSDS of Everolimus

Macimorelin The metabolism of Everolimus can be decreased when combined with Macimorelin. Hydrocortisone cypionate The metabolism of Everolimus can be decreased when combined with Hydrocortisone cypionate. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Everolimus. Agmatine The metabolism of Everolimus can be decreased when combined with Agmatine.

Fluvoxamine The metabolism of Everolimus can be decreased when combined with Fluvoxamine.

Everolimus

Fluocortin The risk or severity of adverse effects can be increased when Everolimus is combined with Fluocortin. Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Everolimus. Clofibrate The metabolism of Everolimus can be increased when combined with Clofibrate. Astemizole The serum concentration of Everolimus can be increased when it is combined with Astemizole. Annamycin The serum concentration of Everolimus can be increased when it is combined with Annamycin.

  DINCOLO DE BINE DINCOACE DE RAU.DESPRE IUBIRE PDF

Gramicidin D The serum concentration of Everolimus can be increased when it is combined with Gramicidin D. Dienogest The metabolism of Everolimus can be decreased when combined with Dienogest. Nisoldipine The serum concentration of Everolimus can be increased when it is combined with Nisoldipine. Medrogestone The metabolism of Everolimus can be decreased when combined with Medrogestone.

Norgestimate The metabolism of Everolimus can be increased when combined with Norgestimate. Glyburide The serum concentration of Everolimus can be increased when it is combined with Glyburide. Hydrocortisone succinate The metabolism of Everolimus can be increased when combined with Hydrocortisone succinate.

Everolimus CAS#:

Castanospermine The risk or severity of adverse effects can be increased when Everolimus is combined with Castanospermine. Nimodipine The serum concentration of Everolimus can be increased when it is combined with Nimodipine. Everoilmus The serum concentration of Ombitasvir can be increased when it is combined with Everolimus.

Clotiazepam The metabolism of Everolimus can be decreased when combined with Clotiazepam. Dexniguldipine The serum concentration of Everolimus can be increased when it is combined with Dexniguldipine.

Oxymorphone The metabolism of Everolimus can be decreased when combined with Oxymorphone. Cilazapril The risk or severity of adverse effects can be increased everilimus Everolimus is combined with Cilazapril.

Gefitinib The serum concentration of Everolimus can be increased when it is combined with Gefitinib. Various common side effects include Bloating or swelling of the face, arms, hands, lower legs, or fee bloody nose, chest pain or tightness, chills, cough, decreased weight, diarrhea, difficult or labored breathing, difficulty with swallowing, fever, general feeling everolimmus discomfort or illness, hoarseness, lower back or side pain, painful or difficult urination, everolimmus weight gain, sores, ulcers, or white spots on the lips, tongue, or inside the mouth and tingling of the hands or feet [23].

Methadone The serum concentration of Everolimus can be increased when it is combined with Methadone. Candicidin The metabolism of Everolimus can be decreased when combined with Candicidin.

Ceftriaxone The serum concentration of Everolimus can be increased when it is combined with Ceftriaxone. Azatadine The metabolism of Everolimus can be increased when combined with Azatadine.

  CP 636 FIRESTOP MORTAR PDF

Cilostazol The metabolism of Everolimus can be decreased when combined with Cilostazol. Apixaban The metabolism of Everolimus can be decreased when combined with Apixaban. Everolimuus The metabolism of Everolimus can be decreased when combined with Cariprazine.

Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Everolimus.

Gusperimus The risk or severity of adverse effects can be increased when Everolimus is combined with Gusperimus. Avoid contact with eyes, skin, and clothing. Balaglitazone The metabolism of Everolimus can be decreased when combined with Balaglitazone. Paramethadione The metabolism of Everolimus can be decreased when combined with Paramethadione. Since it may harm the unborn baby as well as affect fertility the capability to have eberolimuswomen should take effective birth control during administration of Everolimus and for at least eight weeks after stopping drugs.

Carbomycin The metabolism of Everolimus dverolimus be decreased when everooimus with Carbomycin. Benfluorex The therapeutic efficacy of Benfluorex can be decreased when used in combination with Everolimus. Chloroquine The serum concentration of Everolimus can be increased when it is combined with Chloroquine.

Metergoline The serum concentration of Metergoline can be increased when it is combined with Everolimus. Japanese encephalitis virus strain sa antigen formaldehyde inactivated The therapeutic efficacy of Japanese encephalitis virus strain sa antigen formaldehyde inactivated can be decreased when used in combination with Everolimus.

Letrozole The metabolism of Everolimus can be decreased when combined with Letrozole. Glatiramer The risk or severity of adverse effects can be increased when Everolimus is combined with Glatiramer. Cabozantinib The metabolism of Everolimus can be decreased when combined with Cabozantinib. Exemestane The metabolism of Everolimus can be decreased when combined with Exemestane.